News Release(2025)

2025
-
May 8, 2025
Notice Concerning the Results of the Acquisition of Treasury Shares, Through Off-Auction Treasury Share Repurchase Trading System (ToSTNeT-3), the Completion of Acquisition of Treasury shares and the Cancellation of Treasury Shares
-
May 7, 2025
The New Five-Years Medium-Term Management Plan "Beyond 80"
-
May 7, 2025
Notice Concerning Dividends of Surplus (Increase in Dividend)
-
May 7, 2025
Notice on the Acquisition of Treasury Shares, the Acquisition of Treasury Shares Through Off-Auction Own Share Repurchase Trading System (ToSTNeT-3) and the Cancellation of Treasury Shares
-
May 7, 2025
Notice Concerning Revision of the Executive Compensation System
-
April 1, 2025
The Opening of a new Office for Open Innovation in the Boston Area
-
March 31, 2025
Kissei Initiates Phase III Clinical Trial for GnRH Antagonist "Linzagolix" Indicated for Endometriosis
-
March 14, 2025
Kissei Initiates Additional Phase III Clinical Trial for Rovatirelin (KPS-0373) for the Treatment of Spinocerebellar Degeneration
-
February 26, 2025
Submission of New Drug Application for GnRH Antagonist "Linzagolix" Indicated for Uterine Fibroids, in Japan
-
January 21, 2025
Marketing Authorization for the Oral Spleen Tyrosine Kinase Inhibitor TAVALISSE® in South Korea
-
January 14, 2025
Notification of co-promotion agreement termination of Minirin Melt and Desmopressin formulations
-
January 7, 2025
Sub-licensing Agreement for the Oral Spleen Tyrosine Kinase Inhibitor TAVALISSE® with Tai Tien Pharmaceuticals in Taiwan